CytomX Therapeutics, Inc. (CTMX) Total liabilities 2016–2025
CytomX Therapeutics, Inc. (CTMX) total liabilities at each fiscal year-end, per SEC filings.
$52.6MFY2025 · since FY2016: $120.6M → $52.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $52.6M | -56.6% |
| FY2024 | $121.0M | -51.5% |
| FY2023 | $249.2M | -28.1% |
| FY2022 | $346.6M | +2.0% |
| FY2021 | $339.9M | -7.3% |
| FY2020 | $366.4M | +26.3% |
| FY2019 | $290.2M | -11.1% |
| FY2018 | $326.2M | -0.5% |
| FY2017 | $327.7M | +171.7% |
| FY2016 | $120.6M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice